| dc.contributor.author |
Weecharangsan W. |
|
| dc.contributor.author |
Opanasopit P. |
|
| dc.contributor.author |
Niyomtham N. |
|
| dc.contributor.author |
Yingyongnarongkul B.-E. |
|
| dc.contributor.author |
Kewsuwan P. |
|
| dc.contributor.author |
Lee R.J. |
|
| dc.date.accessioned |
2021-04-05T03:21:58Z |
|
| dc.date.available |
2021-04-05T03:21:58Z |
|
| dc.date.issued |
2017 |
|
| dc.identifier.issn |
2507005 |
|
| dc.identifier.other |
2-s2.0-85032161426 |
|
| dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/12994 |
|
| dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032161426&doi=10.21873%2fanticanres.12085&partnerID=40&md5=6d730df18e244e989a66841bcef36e08 |
|
| dc.description.abstract |
Background/Aim: This study investigated the codelivery of plasmid DNA and antisense oligodeoxyribonucleotide (AS ODN) into carcinoma cells by cholic acidmodified polyethylenimine (PEI-CA). Materials and Methods: PEI-CA/plasmid DNA and AS ODN complexes were formulated and evaluated for delivery of plasmid DNA and AS ODN in HeLa cells. The efficiency of co-delivery of plasmid DNA and AS ODN was evaluated by cell growth inhibition using p53 and bcl-2 AS ODN. Results: AS ODN intracellular delivery and green fluorescent protein expression upon cellular transfection were greater than in cells treated with uncomplexed nucleic acids. Treatment of the cells with PEI-CA/p53 plasmid DNA and bcl-2 AS ODN complexes resulted in cell growth inhibition that was greater than that of either PEI-CA/p53 plasmid DNA complexes or PEI-CA/bcl-2 AS ODN complexes alone. Conclusion: The co-delivery of p53 plasmid DNA and bcl-2 AS ODN in PEI-CA complexes enhanced therapeutic activities of both p53 plasmid DNA and bcl-2 AS ODN. |
|
| dc.subject |
antisense oligodeoxynucleotide |
|
| dc.subject |
cholic acid |
|
| dc.subject |
green fluorescent protein |
|
| dc.subject |
plasmid DNA |
|
| dc.subject |
polyethyleneimine |
|
| dc.subject |
protein bcl 2 |
|
| dc.subject |
protein p53 |
|
| dc.subject |
antisense oligodeoxynucleotide |
|
| dc.subject |
BCL2 protein, human |
|
| dc.subject |
protein bcl 2 |
|
| dc.subject |
protein p53 |
|
| dc.subject |
agar gel electrophoresis |
|
| dc.subject |
antineoplastic activity |
|
| dc.subject |
Article |
|
| dc.subject |
cancer inhibition |
|
| dc.subject |
carcinoma cell |
|
| dc.subject |
cell culture |
|
| dc.subject |
cell growth |
|
| dc.subject |
controlled study |
|
| dc.subject |
fluorescence activated cell sorting |
|
| dc.subject |
genetic transfection |
|
| dc.subject |
growth inhibition |
|
| dc.subject |
human |
|
| dc.subject |
human cell |
|
| dc.subject |
nonviral gene delivery system |
|
| dc.subject |
particle size |
|
| dc.subject |
priority journal |
|
| dc.subject |
protein expression |
|
| dc.subject |
zeta potential |
|
| dc.subject |
antagonists and inhibitors |
|
| dc.subject |
carcinoma |
|
| dc.subject |
cell proliferation |
|
| dc.subject |
drug effects |
|
| dc.subject |
drug potentiation |
|
| dc.subject |
gene therapy |
|
| dc.subject |
gene vector |
|
| dc.subject |
genetics |
|
| dc.subject |
HeLa cell line |
|
| dc.subject |
metabolism |
|
| dc.subject |
pharmacology |
|
| dc.subject |
plasmid |
|
| dc.subject |
Carcinoma |
|
| dc.subject |
Cell Proliferation |
|
| dc.subject |
Drug Synergism |
|
| dc.subject |
Genetic Therapy |
|
| dc.subject |
Genetic Vectors |
|
| dc.subject |
Green Fluorescent Proteins |
|
| dc.subject |
HeLa Cells |
|
| dc.subject |
Humans |
|
| dc.subject |
Oligodeoxyribonucleotides, Antisense |
|
| dc.subject |
Plasmids |
|
| dc.subject |
Proto-Oncogene Proteins c-bcl-2 |
|
| dc.subject |
Tumor Suppressor Protein p53 |
|
| dc.title |
Synergistic inhibition of human carcinoma cell growth via co-delivery of p53 plasmid DNA and bcl-2 antisense oligodeoxyribonucleotide by cholic acid-modified polyethylenimine |
|
| dc.type |
Article |
|
| dc.rights.holder |
Scopus |
|
| dc.identifier.bibliograpycitation |
Anticancer Research. Vol 37, No.11 (2017), p.6335-6340 |
|
| dc.identifier.doi |
10.21873/anticanres.12085 |
|